Gynaekologisches Zentrum Bonn

Verified siteinfo

Germany Friedensplatz 16, Zentrum, 53111 Bonn, Germany

6 trials recruiting
Breast cancer · Triple negative breast cancer · Actinic keratosis
Adults and children

About Specializations

Gynaekologisches Zentrum Bonn in Bonn, Germany specialises in clinical trials of conditions such as Breast cancer, Triple negative breast cancer, Actinic keratosis, Chronic spontaneous urticaria, and other specialisations. This site conducts important research.

Main research areas of the site

Triple Negative Breast Cancer (TNBC) – Immunotherapy Trials

The research at Gynaekologisches Zentrum Bonn focuses on Triple Negative Breast Cancer, evaluating innovative neoadjuvant and adjuvant strategies to improve outcomes.

Neoadjuvant immunotherapy combined with chemotherapy
Assessment of pathological complete response (pCR)
Long‑term event‑free survival monitoring

By integrating pembrolizumab into treatment regimens, the site aims to increase cure rates and provide new therapeutic options for patients with this aggressive disease.

Contraceptive Research – Levonorgestrel Vaginal Delivery System

Studies conducted in the gynecology department investigate the Levonorgestrel Vaginal Delivery System to determine its effectiveness as a reliable birth control method.

Hormonal contraceptive efficacy across multiple cycles
Safety and tolerability in reproductive‑age women
User acceptability and adherence to treatment schedule

The trial seeks to demonstrate robust contraceptive efficacy, offering an additional safe option for family planning at the Bonn center.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Friedensplatz 16, Zentrum53111 BonnGermany

Open in maps ↗

Recruiting now: 6 trials
Conditions studied: 17
Partner status: Verified site

More sites in Bonn Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

23 clinical trials

Triple negative breast cancer

Recruiting

A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer

Registered drugNo placebo

A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Durvalumab
Sponsor:Queen Mary University Of London

Contact Research Centre

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

HER2 positive breast cancer

Recruiting

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer